ARTIN BIOSCIENCE

Committed to Respiratory Therapies and Allergies

Artin Bioscience's mission is to develop and provide therapies for respiratory diseases and immune system allergic reactions.  Our lead indications being Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension (PAH) and Severe Asthma.

We have recently licensed a Peanut Allergy molecule to be managed by a separate entity and team after clinical phase 1 trials complete.

Phase 2 trials for PAH have started and phase 2 trials for COPD are scheduled for 2026.